Ten billion US dollars of inhaler market, domestic enterprises began to make efforts!

[pharmaceutical network market analysis] recently, omini pharmaceutical announced a cooperation agreement with a large pharmaceutical company in India The two sides will work together to develop a inhalation powder mist product, which will target the US / Europe / Canada COPD / asthma market of 10 billion US dollars It is understood that inhalation preparations refer to liquid or solid preparations that are dissolved or dispersed in a suitable medium and delivered to the lungs in the form of vapor or aerosol to play a local or systemic role Compared with tablets, inhaled preparation can reach the focus directly, with less adverse reactions Therefore, at present, the respiratory diseases are mainly treated with inhalers, which have incomparable advantages in the treatment of respiratory diseases such as asthma and COPD In particular, compared with conventional preparations, the advantages of inhalers are that they can directly enter the blood from the lung and have quick effect; local administration can improve the accumulation of drugs in the target organs, increase the efficacy and reduce the toxic and side effects; there is no first pass effect and high bioavailability Up to now, hundreds of inhalation products have been listed in the world They can be divided into dry powder inhalers (DPI), aerosols (MDI), aerosols and inhalation solutions according to the design of products According to the data, in 2018, the global market for asthma and COPD drugs has exceeded US $52.5 billion, including US $43.7 billion for inhaled drugs, accounting for 83.2%; US $35.7 billion for inhaled drugs, accounting for 86.1%, among which, the market share of inhaled powder mist is higher, accounting for 41%, and that of inhaled aerosol is second, accounting for about 40% In addition, it is predicted that the global brand drug market of asthma / COPD will remain at US $26.06 billion in 2020 At present, the global asthma / COPD brand drug market presents a monopolistic competition pattern, in which GSK accounts for 39% of the market share, ranking first in the world, followed by AstraZeneca (AZ) and bringer Ingelheim (BI), accounting for 19% and 13% of the market share respectively Looking back at the domestic market, in the past few years, the domestic inhalation preparation market is also rising rapidly, in which asthma and COPD drugs occupy the leading position in the inhalation preparation market In 2018, the sales volume of China's inhalation preparation sample hospitals reached 3.626 billion yuan, up 10.7% year on year, and in the first half of 2019, the sales volume reached 2.111 billion yuan However, due to the limitations of preparation technology, patents and other barriers, currently, the inhalation preparations in China's market are mainly dominated by foreign pharmaceutical enterprises such as AstraZeneca, GSK, and Bi However, in recent years, China has invested more and more in respiratory medicine research, and the market share of domestic asthma and COPD inhaled dosage forms is gradually increasing And with the breakthrough of domestic enterprises in the technical barriers of inhalation preparations, more and more enterprises are also starting to layout this blue ocean market According to the analysis of investors, in the general environment, the rise of domestic pharmaceutical enterprises of inhalation preparations is coming, and they are optimistic about the enterprises with high progress and strong sales ability The market prospect of asthma and inhalant preparations in China is broad, and the rising tide of domestic pharmaceutical enterprises is expected to come along with the listing of domestic imitated varieties The industry is generally optimistic about the enterprises with advanced layout, R & D progress and strong academic promotion ability in the field of heavyweight varieties, focusing on recommending China biopharmaceutical (H), Hengrui pharmaceutical, jiankangyuan, Xianju pharmaceutical, etc.